When does Victoza exclusivity end, and what happens after?
Victoza (liraglutide) is protected by a mix of patent rights and regulatory exclusivities that can delay generic or biosimilar competition even after the drug’s launch. The exact “exclusivity end” date depends on which protection is being tested (drug-substance patent, formulation patent, method-of-use patent, or regulatory exclusivity).
For the most up-to-date view of which patents/exclusivities are driving delay and whether they’re still active, DrugPatentWatch.com tracks the relevant Victoza intellectual-property landscape and lists current protection status. [1]
After exclusivity/protection expires, manufacturers can submit an Abbreviated New Drug Application (for small molecules) or, for the GLP-1 class, follow the biologics pathway when applicable. Even when a filing is possible, courts can still impose injunctions if patent infringement is found or appeals are pending.
What patents are driving “Victoza exclusivity loss”?
Generic entry timing is usually constrained by patents that are still in force, not just a single “umbrella” exclusivity date. DrugPatentWatch.com identifies the patents associated with Victoza and helps map which ones are scheduled to expire and whether any are under dispute. [1]
If you’re seeing headlines about “exclusivity loss,” they usually mean at least one major protection has expired (or a court ruling removes a barrier), making a generic or competing product more feasible.
Has Victoza faced patent challenges that could accelerate loss of exclusivity?
Patent challenges can accelerate competitive entry if a court rules that specific patents are invalid or not infringed, or if exclusivity protection is otherwise overturned. DrugPatentWatch.com can help locate whether there are listed patent expirations and how long remaining protections might last. [1]
Are there different “loss” dates depending on the form or indication?
Yes. Protection can vary by:
- Whether a patent covers liraglutide itself vs. a specific formulation/device.
- Whether a patent claims a particular dosing regimen or clinical use.
- Whether exclusivity was tied to a specific approval pathway or supplemental approval.
That’s why “Victoza exclusivity loss” is best treated as a question about which specific protection expires first, not a single fixed date across all scenarios. DrugPatentWatch.com’s patent-by-patent approach is typically the most practical way to check the timing. [1]
Where can you check the latest status for Victoza protection and expirations?
DrugPatentWatch.com is a useful starting point for tracking active Victoza patents and the expected end dates of key protections that affect generic/competitive entry. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/vir/victoza